{"doi":"10.7554/elife.83694","title":"Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial","abstract":"Background: Cancer patients show increased morbidity with COVID-19 and need effective immunization strategies. Many healthcare regulatory agencies recommend administering 'booster' doses of COVID-19 vaccines beyond the standard two-dose series, for this group of patients. Therefore, studying the efficacy of these additional vaccine doses against SARS-CoV-2 and variants of concern is of utmost importance in this immunocompromised patient population. Methods: We conducted a prospective single arm clinical trial enrolling patients with cancer that had received two doses of mRNA or one dose of AD26.CoV2.S vaccine and administered a third dose of mRNA vaccine. We further enrolled patients that had no or low responses to three mRNA COVID vaccines and assessed the efficacy of a fourth dose of mRNA vaccine. Efficacy was assessed by changes in anti-spike antibody, T-cell activity, and neutralization activity, which were again assessed at baseline and 4 weeks. Results: We demonstrate that a third dose of COVID-19 vaccine leads to seroconversion in 57% of patients that were seronegative after primary vaccination series. The immune response is durable as assessed by anti-SARS-CoV-2 (anti-S) antibody titers, T-cell activity, and neutralization activity against wild-type (WT) SARS-CoV2 and BA1.1.529 at 6 months of follow-up. A subset of severely immunocompromised hematologic malignancy patients that were unable to mount an adequate immune response (titer <1000 AU/mL) after the third dose and were treated with a fourth dose in a prospective clinical trial which led to adequate immune boost in 67% of patients. Low baseline IgM levels and CD19 counts were associated with inadequate seroconversion. Booster doses induced limited neutralization activity against the Omicron variant. Conclusions: These results indicate that third dose of COVID vaccine induces durable immunity in cancer patients and an additional dose can further stimulate immunity in a subset of patients with inadequate response. Funding: Leukemia Lymphoma Society, National Cancer Institute. Clinical trial number: NCT05016622.","journal":"eLife","year":2023,"id":324595,"datarank":1.0233871961646717,"base_score":3.5263605246161616,"endowment":3.5263605246161616,"self_citation_contribution":0.5289540786924243,"citation_network_contribution":0.4944331174722473,"self_endowment_contribution":0.5289540786924243,"citer_contribution":0.4944331174722473,"corpus_percentile":null,"corpus_rank":null,"citation_count":33,"citer_count":21,"citers_with_citation_signal":18,"citers_with_endowment":18,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9575,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT05016622"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":586705,"name":"Kith Pradhan","orcid":"0000-0001-7089-1652","position":1,"is_corresponding":false},{"id":1042044,"name":"Benjamin Duva","orcid":null,"position":2,"is_corresponding":false},{"id":360832,"name":"Juan Manuel Carreño","orcid":"0000-0002-9039-9275","position":3,"is_corresponding":false},{"id":320298,"name":"Srabani Sahu","orcid":"0009-0002-3667-3592","position":4,"is_corresponding":false},{"id":620189,"name":"Victor Thiruthuvanathan","orcid":"0000-0001-6773-0700","position":5,"is_corresponding":false},{"id":559467,"name":"Sean Campbell","orcid":"0000-0001-5465-5107","position":6,"is_corresponding":false},{"id":1041273,"name":"Sonia Gallego","orcid":"0000-0002-7792-9876","position":7,"is_corresponding":false},{"id":347352,"name":"Tushar D. Bhagat","orcid":"0000-0002-4527-5505","position":8,"is_corresponding":false},{"id":39795,"name":"Johanna Rivera","orcid":"0000-0001-9332-4861","position":9,"is_corresponding":false},{"id":865054,"name":"Gaurav S. Choudhary","orcid":"0000-0001-5365-6706","position":10,"is_corresponding":false},{"id":149332,"name":"Raul Olea","orcid":null,"position":11,"is_corresponding":false},{"id":1042045,"name":"Maite Sabalza","orcid":null,"position":12,"is_corresponding":false},{"id":858888,"name":"Lauren Shapiro","orcid":"0000-0003-0138-8986","position":13,"is_corresponding":false},{"id":759584,"name":"Matthew Lee","orcid":"0000-0001-7103-4660","position":14,"is_corresponding":false},{"id":1037380,"name":"Ryann Quinn","orcid":null,"position":15,"is_corresponding":false},{"id":1041274,"name":"Ioannis Mantzaris","orcid":"0000-0001-8346-5767","position":16,"is_corresponding":false},{"id":516391,"name":"Edward Chu","orcid":"0000-0002-0908-5325","position":17,"is_corresponding":false},{"id":620191,"name":"Britta Will","orcid":"0000-0002-9534-6690","position":18,"is_corresponding":false},{"id":504851,"name":"Liise-anne Pirofski","orcid":"0000-0002-7568-2961","position":19,"is_corresponding":false},{"id":103779,"name":"Florian Krammer","orcid":"0000-0003-4121-776X","position":20,"is_corresponding":false},{"id":581674,"name":"Amit Verma","orcid":"0000-0002-5408-1673","position":21,"is_corresponding":false},{"id":263560,"name":"Balázs Halmos","orcid":"0000-0001-7548-8360","position":22,"is_corresponding":false},{"id":636679,"name":"Astha Thakkar","orcid":"0000-0001-7778-0752","position":0,"is_corresponding":true}],"reference_count":50,"raw_metadata":null,"created_at":"2026-07-19T01:08:16.809511Z","pmid":"36975207","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}